ArticleMolecular cancer research : MCR2011
Contribution of xanthine oxidoreductase to mammary epithelial and breast cancer cell differentiation in part modulates inhibitor of differentiation-1.
Article in Molecular cancer research : MCR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Association between serum uric acid to albumin ratio and all-cause mortality in critically ill patients with sepsis: a retrospective study.BMC infectious diseases · 2025Article
- Xanthine oxidoreductase expression is diminished in breast cancer as a response to uric acid mediated chelation of redox active iron.Free radical biology & medicine · 2025Article
- Machine learning-assisted quantitative metabolomics of West African patients with advanced breast cancer.Scientific reports · 2025Article
- Metabolic Profiling of Breast Cancer Cell Lines: Unique and Shared Metabolites.International journal of molecular sciences · 2025Article
- Prognostic value of circulating uric acid in gastrointestinal cancers, a systematic review and meta-analysis.Gastroenterology and hepatology from bed to bench · 2025Review
- Exploring the causal association between uric acid and lung cancer in east Asian and European populations: a mendelian randomization study.BMC cancer · 2024Article
- Association of serum uric acid to lymphocyte ratio, a novel inflammatory biomarker, with risk of stroke: A prospective cohort study.CNS neuroscience & therapeutics · 2023Article
- Mass Spectrometry-Based Proteomics of Human Milk to Identify Differentially Expressed Proteins in Women with Breast Cancer versus Controls.Proteomes · 2022Article
- The double faced role of xanthine oxidoreductase in cancer.Acta pharmacologica Sinica · 2022Review
- Establishing pteridine metabolism in a progressive isogenic breast cancer cell model - part II.Metabolomics : Official journal of the Metabolomic Society · 2022Article
- Establishing pteridine metabolism in a progressive isogenic breast cancer cell model.Metabolomics : Official journal of the Metabolomic Society · 2021Article
- Brief report: The uricase mutation in humans increases our risk for cancer growth.Cancer & metabolism · 2021Article
- The Adipokine Component in the Molecular Regulation of Cancer Cell Survival, Proliferation and Metastasis.Pathology oncology research : POR · 2021Review
- Friend or Foe? An Unrecognized Role of Uric Acid in Cancer Development and the Potential Anticancer Effects of Uric Acid-lowering Drugs.Journal of Cancer · 2020Review
- Targeted knock-in mice expressing the oxidase-fixed form of xanthine oxidoreductase favor tumor growth.Nature communications · 2019Article
- Deep Learning Accurately Predicts Estrogen Receptor Status in Breast Cancer Metabolomics Data.Journal of proteome research · 2018Article
- Alcohol abuse is associated with enhanced pulmonary and systemic xanthine oxidoreductase activity.American journal of physiology. Lung cellular and molecular physiology · 2017Article
- Xanthine oxidoreductase is required for genotoxic stress-induced NKG2D ligand expression and gemcitabine-mediated antitumor activity.Oncotarget · 2016Article
- Prognostic value of pre-operative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy.Cancer biomarkers : section A of Disease markers · 2016Article
- Xanthine oxidoreductase in cancer: more than a differentiation marker.Cancer medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Loss of xanthine oxidoreductase (XOR) has been linked to aggressive breast cancer in vivo and to breast cancer cell aggressiveness in vitro. In the present study, we hypothesized that the contribution of XOR to the development of the normal mammary gland may underlie its capacity to modulate breast cancer. We contrasted in vitro and in vivo developmental systems by differentiation marker and microarray analyses. Human breast cancer microarray was used for clinical outcome studies. The role of XOR in differentiation and proliferation was examined in human breast cancer cells and in a mouse xenograft model. Our data show that XOR was required for functional differentiation of mammary epithelial cells both in vitro and in vivo. Poor XOR expression was observed in a mouse ErbB2 breast cancer model, and pharmacologic inhibition of XOR increased breast cancer tumor burden in mouse xenograft. mRNA microarray analysis of human breast cancer revealed that low XOR expression was significantly associated with time to tumor relapse. The opposing expression of XOR and inhibitor of differentiation-1 (Id1) during HC11 differentiation and mammary gland development suggested a potential functional relationship. While overexpression of Id1 inhibited HC11 differentiation and XOR expression, XOR itself modulated expression of Id1 in differentiating HC11 cells. Overexpression of XOR both inhibited Id1-induced proliferation and -stimulated differentiation of Heregulin-β1-treated human breast cancer cells. These results show that XOR is an important functional component of differentiation whose diminished expression contributes to breast cancer aggressiveness, and they support XOR as both a breast cancer biomarker and a target for pharmacologic activation in therapeutic management of aggressive breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.